Reelevant is a company that specializes in hyper-personalized customer experience solutions, focusing on enhancing the last mile of customer interactions. Founded in 2016, Reelevant aims to reconnect brands with their customers by creating memorable brand moments and maximizing customer lifetime value (CLTV). The company achieves this by converting data into relevant content that is generated and synchronized in real time, tailored to each customer's specific context across all digital touchpoints. Reelevant's technology improves email marketing by collecting and analyzing a wide range of real-time data, enabling businesses to engage customers more effectively and accelerate revenue by delivering timely, relevant messages. The company has collaborated with various prominent brands, including Carrefour, Décathlon, L'Oréal, and Leroy Merlin.
Flexvelop is a Hamburg-based fintech company that specializes in providing an embedded payment solution for financing business equipment at the point of sale and online. The company's service allows business customers to rent fully insured equipment with the added flexibility to purchase or return it at any time. By utilizing a patented in-house financing technology, Flexvelop streamlines the leasing process, offering a quicker and more adaptable alternative to traditional methods. This approach not only supports businesses, including startups and medium-sized companies, in acquiring essential tools but also promotes sustainability by facilitating the circular economy, enabling retailers and manufacturers to enhance sales while operating with the latest equipment.
Seaweed Concept is a marine biotechnology company, that focuses on the innovative utilization of seaweed to provide high-quality ingredients to various industrial sectors
Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
Anybuddy is a leading sports booking marketplace in France, specializing in racket sports. The company has developed a sports application that allows users to find players and book pitches for football and tennis matches. Its platform provides access to numerous clubs, facilitating reservations and payments without requiring a license or subscription. Users can access a wide selection of quality tennis courts and various playing surfaces, all at competitive prices. Anybuddy aims to simplify the process of booking sports facilities and encourage more participation in physical activities.
Karmen is a revenue-based financing firm that provides non-dilutive financing solutions to digital businesses, facilitating rapid and flexible access to capital. The platform streamlines the funding process, allowing companies to quickly secure financing for various purposes, including customer acquisition, recruitment, and inventory needs. Karmen integrates seamlessly with existing business tools and employs secured API connections to analyze data and deliver detailed performance dashboards. This approach enables users to receive funding approvals in a short timeframe, thereby accelerating their growth and financial agility.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Bsport solution is a software platform for boutique fitness studios. From marketing, live classes, group class and appointment management, invoicing and teacher management, they help studios and boutique fitness manage their activities while creating new revenue streams. Everyone can access every tool and feature without the need for multiple add-ons or integrations by using its custom all-inclusive software. Whatever its priorities and preferences are, its platform is tailored to fit all business types and industries.
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.
Syroco is a scientific and technical laboratory based in Marseille, France, established in 2019. The company focuses on enhancing efficiency in the energy and transportation sectors through innovative solutions. Syroco specializes in developing a speed craft with the aim of breaking sailing speed records and engages in projects that involve designing and building advanced engineering systems. The team comprises diverse professionals, including a kitesurfer, a two-time world sailing speed record holder, digital entrepreneurs, and a naval architect. Syroco's approach includes tackling "moonshot challenges," which are ambitious technological endeavors. Additionally, the company employs data and artificial intelligence to create modeling software that supports the energy transition in maritime transportation, facilitating the optimization of operational and energy efficiency for both on-board and shore applications.
Dashbook is a collaborative publishing house that empowers authors and readers.
Developer of a human resources platform designed to augment employee engagement. The company's platform unifies human resources and information technology by centralizing employee data and quantifying KPIs, enabling companies to create an employee-centric workspace and personalized employee experience.
Otoqi specializes in developing an automotive management platform that streamlines the entire lifecycle of vehicles. The company's technology simplifies the logistics involved in moving, servicing, charging, repairing, and delivering a large number of vehicles. By facilitating instant ordering and providing real-time visibility and control during the buying process of new and used cars, Otoqi enhances operational efficiency. Additionally, it enables quick transfers of vehicles between various sites, agencies, and partners, while also offering comprehensive vehicle testing and after-sales services. This holistic approach allows mobility operators to access a full range of services tailored to their needs.
Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.
Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.
Sinay is a company that specializes in providing solutions for stakeholders in the maritime sector through the collection and analysis of maritime data. It has developed a big data platform aimed at studying the marine environment, which combines advanced data technologies with a fully integrated system. This platform offers maritime analytics, facilitates easy maritime surveys, and provides user-friendly dashboards. By equipping maritime industries with the necessary resources to manage increasing data volumes and complex analytics, Sinay aims to enhance decision-making and operational efficiency within the maritime sector.
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.
ID5 is focused on enhancing online advertising for consumers, media owners, and advertisers, with the goal of helping publishers achieve sustainable revenue growth. The company offers a transparent and privacy-compliant identity infrastructure that replaces third-party cookies and mobile advertising IDs with a stable, consented, and encrypted user ID. This solution improves user recognition and match rates, enabling publishers to better monetize their audiences and helping advertisers run effective and measurable campaigns. Additionally, ID5's platform addresses inefficiencies in website campaign performance by managing cookie synchronization among partners, ensuring privacy compliance, and streamlining consent management. This ultimately enhances the user experience, increases page load speeds, and allows clients such as publishers and data providers to operate more efficiently while maximizing the value of their data and inventory.
Peptobiotics is a synbio startup that develops livestock disease prevention biotechnology for sustainable Agri productivity. The company makes agriculture more productive, humane, and sustainable by promoting growth and protecting against pathogens using a new type of antibiotic alternative that does not cause resistance.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.
Starfish Bioscience specializes in developing microbiological solutions for agriculture and vineyards, aiming to regenerate soils by restoring their microbiomes. The company provides analysis of soil microbiomes and creates innovative solutions to enhance soil health and crop yields. By focusing on sustainability and productivity, Starfish Bioscience seeks to minimize environmental impact and address future challenges in global agriculture, ultimately contributing to the well-being of humanity and the preservation of the Earth.
Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.
Nimble Science Ltd. is a digital health company focused on transforming gastrointestinal health through its innovative SIMBA capsule technology. This platform enables the passive sampling of small bowel luminal fluid, allowing for the collection of precision datasets related to the gastrointestinal tract. By utilizing multi-omic mapping, Nimble Science provides healthcare providers with direct insights into specific regions of the GI system, facilitating improved diagnosis and treatment strategies. The company's approach represents a significant advancement in understanding and managing gastrointestinal health.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.
Pitchy is a video creation platform that offers a software-as-a-service (SaaS) solution, allowing users to produce professional videos quickly and easily, without needing technical skills. Users can select from a range of ready-to-use templates tailored for various scenarios, such as investor pitches or product descriptions. By uploading their own text, images, logos, and videos, users can generate a finished video in just a few minutes. Pitchy provides the option to purchase individual videos or opt for a monthly subscription, during which the company hosts the videos on its Vimeo account. The platform incorporates motion design templates crafted by Pitchy's designers using Adobe After Effects, enabling businesses to create engaging and interactive content that helps drive customer acquisition and enhance sales.
Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.
Hepster is an InsurTech company that specializes in creating customized insurance products and seamlessly integrating them into digital processes. Operating under a B2B model, Hepster enhances its offerings with a B2C webshop that allows consumers direct access to its services. The company utilizes a fully API-driven, cloud-based, and modular approach to develop and deploy digital insurance solutions tailored to the specific needs of its partners. Hepster's product portfolio focuses on various sectors, including bike, e-bike, electronics, and sports equipment insurance, thereby providing a comprehensive experience for clients across the insurance value chain.
Sekoia.io develops a unified security platform aimed at enhancing the capabilities of security operations (SecOps) teams in combating cyber threats. The platform enables organizations to automatically identify and respond to significant incidents across their entire attack surface, leveraging integrated intelligence and real-time detection. By continuously analyzing emerging threats, Sekoia.io equips clients with the necessary strategies to stay updated and effectively address new challenges. Its approach allows security teams to manage the complexities of cybersecurity with improved speed and reliability, ultimately strengthening their overall security posture.
Sinay is a company that specializes in providing solutions for stakeholders in the maritime sector through the collection and analysis of maritime data. It has developed a big data platform aimed at studying the marine environment, which combines advanced data technologies with a fully integrated system. This platform offers maritime analytics, facilitates easy maritime surveys, and provides user-friendly dashboards. By equipping maritime industries with the necessary resources to manage increasing data volumes and complex analytics, Sinay aims to enhance decision-making and operational efficiency within the maritime sector.
Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.
Bsport solution is a software platform for boutique fitness studios. From marketing, live classes, group class and appointment management, invoicing and teacher management, they help studios and boutique fitness manage their activities while creating new revenue streams. Everyone can access every tool and feature without the need for multiple add-ons or integrations by using its custom all-inclusive software. Whatever its priorities and preferences are, its platform is tailored to fit all business types and industries.
Graphite Innovation & Technologies specializes in developing innovative and sustainable smart coating solutions tailored for the shipping industry. The company employs advanced nanotechnology to create environmentally friendly paints that are designed to minimize fuel consumption and greenhouse gas emissions for ocean-going vessels. GIT provides a comprehensive range of marine coating systems that enhance vessel efficiency while ensuring that its products are devoid of harmful leaching chemicals. The coatings are hydrophobic and exceptionally durable, preventing marine organisms from attaching to hulls and subsequently reducing drag. As a significant player in the global marine coatings market, GIT is committed to driving sustainability within the maritime sector, positioning itself as a disruptor through its focus on innovation and the practical applications of advanced materials, including graphene and nanoplatelets. The company's approach not only supports environmental goals but also offers cost savings for ship operators by improving operational efficiency.
Glopal is a company that specializes in enhancing e-commerce experiences for merchants aiming to sell internationally. It offers a comprehensive marketing portal that facilitates localization, international shipping, and management of duties and taxes. By utilizing automated localization tools, Glopal enables merchants to reach global buyers in their preferred language and currency. The platform also supports multi-channel traffic generation through search engines and international SEO, allowing businesses to effectively attract and convert customers from various markets. Overall, Glopal provides essential resources for merchants to expand their reach and improve the shopping experience for international customers.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Flexvelop is a Hamburg-based fintech company that specializes in providing an embedded payment solution for financing business equipment at the point of sale and online. The company's service allows business customers to rent fully insured equipment with the added flexibility to purchase or return it at any time. By utilizing a patented in-house financing technology, Flexvelop streamlines the leasing process, offering a quicker and more adaptable alternative to traditional methods. This approach not only supports businesses, including startups and medium-sized companies, in acquiring essential tools but also promotes sustainability by facilitating the circular economy, enabling retailers and manufacturers to enhance sales while operating with the latest equipment.
ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.
Mediarithmics is a cloud-based data marketing platform headquartered in Fontenay-sous-Bois, France, that was established in 2011. It provides a solution for brands to manage retargeting campaigns across multiple devices and enables agencies to handle clients' real-time bidding (RTB) and email campaigns through a unified tool. The platform functions as a next-generation Customer Data Platform (CDP) that encompasses all aspects of Data Management Platforms (DMP) and CDPs. It facilitates the creation of Data Alliances, ensuring data security and compliance with regulations. Mediarithmics' technology allows for the collection of comprehensive customer and prospect data, enabling real-time segmentation and activation of multi-channel marketing campaigns. Clients can also customize the platform by incorporating their own algorithms to enhance marketing personalization and data monetization strategies. Overall, Mediarithmics aims to improve consumer engagement and drive growth through data-driven outreach strategies.
BAOUW / Outdoor Organic Nutrition specializes in the production of organic food products designed for athletes and health-conscious individuals. The company offers a range of items, including organic nutrition bars, purees, energy nuts, and various accessories. Emphasizing natural ingredients, BAOUW focuses on unprocessed components that provide beneficial lipids, vegan proteins, and natural fruit sugar. Their products are formulated to deliver long-lasting energy while being easy to digest and convenient for on-the-go consumption. Through their commitment to gourmet, responsible, and efficient nutrition, BAOUW aims to support individuals in maintaining their health and performance.
Citalid operates a cybersecurity platform that assesses the risks associated with cyber threats through advanced technology. The platform evaluates the likelihood of cyberattacks and estimates their potential financial consequences, enabling businesses to understand and counter such risks effectively. By integrating Cyber Threat Intelligence with risk quantification, Citalid provides a dynamic view of potential threats and simulates various scenarios to model their financial impact. This allows enterprises to better plan and prepare for cyber risks. Additionally, the platform offers tailored security and insurance recommendations, helping organizations make informed decisions regarding their cybersecurity strategies. Citalid also supports insurers by enhancing their understanding of portfolio exposure and facilitating smarter decision-making for their clients regarding cyber risk.
Soan is an online payment solution and a free suite of tools that serve the success of freelance projects.
Standing Ovation is a science to creating an animal-free, planet-friendly, vegan cheese that is still as deliciously dairy as the real thing.
Sentryc is a brand protection firm that specializes in safeguarding companies and their products from online piracy and brand abuse. The firm offers a proprietary software solution that monitors digital marketplaces to detect and document potential counterfeits. By scanning various websites for unauthorized products, Sentryc enables clients to identify instances of trademark abuse and unauthorized dealers. The platform streamlines the reporting process by automatically notifying relevant parties for the removal of infringing listings, thereby helping brands maintain the integrity of their assets and protect their reputation in the digital landscape.
Ideel is the platform that saves time and money by simply managing all its subscriptions in one space: - You view all your expenses, and are notified in case of change of tariff or out of package Unusual, when a subscription arrives at the renewal date, or when a trial period comes to an end - You cancel with a click a subscription or pause it for a period. Whether by registered letter or password, they automate all the steps manage everything without leaving the interface! - You can reduce your expenses or improve the quality of your services without having to manage the formalities.
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Jolimoi is a skincare products company that specializes in beauty and makeup merchandise. Their product range includes face care, hair care, makeup, oils, fragrances, and various accessories suitable for both men and women. The company is focused on providing personalized recommendations to customers based on their individual preferences, enhancing the shopping experience and catering to specific skincare and beauty needs.
One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.
Geovelo is a developer of a navigation application tailored for cyclists. The application provides users with directions and guidance through voice, map, or compass, ensuring they can navigate roads equipped with cycling facilities or low traffic areas. In addition to route navigation, Geovelo helps users discover new rides and plan trips while identifying the most reliable and secure routes. The platform also fosters community engagement, allowing cyclists to connect, participate in challenges, and promote daily cycling as a sustainable mode of transportation.
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.
Hepster is an InsurTech company that specializes in creating customized insurance products and seamlessly integrating them into digital processes. Operating under a B2B model, Hepster enhances its offerings with a B2C webshop that allows consumers direct access to its services. The company utilizes a fully API-driven, cloud-based, and modular approach to develop and deploy digital insurance solutions tailored to the specific needs of its partners. Hepster's product portfolio focuses on various sectors, including bike, e-bike, electronics, and sports equipment insurance, thereby providing a comprehensive experience for clients across the insurance value chain.
HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.
Ecto specializes in technology that merges data and biology to enhance the efficiency and sustainability of the aquaculture industry. By collaborating with farmers, Ecto streamlines production and health management through advanced molecular tools and digital technologies. Their innovative solutions have helped farmers generate over 51 million additional healthy servings of protein. The company operates offices in Boston, Atlanta, and Stavanger, Norway, serving a global customer base. Founded in 2013 at Harvard Innovation Labs by Dmitry Kozachenok and James Webb, Ecto has secured competitive research grants from prominent organizations such as the US National Science Foundation, the US Department of Agriculture, and Innovation Norway. Their farm management platform simplifies data recording and offers real-time insights, enabling farmers to monitor operations effectively, detect diseases, and manage production cycles in challenging environments.
CattleEye is a company based in the United States that specializes in autonomous livestock monitoring systems. Founded in 2019, it offers a cloud-based artificial intelligence platform that analyzes visual imagery of livestock captured through web cameras and other detection equipment. This technology enables farmers to monitor the performance and welfare of their cows by interpreting various behavioral signs, including gait measurements and mobility scores. CattleEye's solution aims to enhance livestock management and improve the protein supply chain, providing a comprehensive tool for livestock farmers to optimize their operations.
Proteon Pharmaceuticals Ltd. is a company based in Lodz, Poland, focused on developing bacteriophage-based products aimed at enhancing animal and human health while promoting environmental sustainability. Established in 2005, Proteon leverages precision biology to create solutions that mitigate the reliance on antibiotics and address the challenges of antimicrobial resistance. The company offers a range of services, including high-throughput screening (HTS) and high-content screening (HCS) tests to identify new active substances with specific immunomodulatory properties. Additionally, Proteon provides contract services for pharmaceutical companies to explore various chemical libraries. Its product pipeline includes solutions designed to improve performance and food safety in poultry, as well as to prevent economically significant bacterial diseases in aquaculture and dairy farming.
Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.
Ecto specializes in technology that merges data and biology to enhance the efficiency and sustainability of the aquaculture industry. By collaborating with farmers, Ecto streamlines production and health management through advanced molecular tools and digital technologies. Their innovative solutions have helped farmers generate over 51 million additional healthy servings of protein. The company operates offices in Boston, Atlanta, and Stavanger, Norway, serving a global customer base. Founded in 2013 at Harvard Innovation Labs by Dmitry Kozachenok and James Webb, Ecto has secured competitive research grants from prominent organizations such as the US National Science Foundation, the US Department of Agriculture, and Innovation Norway. Their farm management platform simplifies data recording and offers real-time insights, enabling farmers to monitor operations effectively, detect diseases, and manage production cycles in challenging environments.
Otoqi specializes in developing an automotive management platform that streamlines the entire lifecycle of vehicles. The company's technology simplifies the logistics involved in moving, servicing, charging, repairing, and delivering a large number of vehicles. By facilitating instant ordering and providing real-time visibility and control during the buying process of new and used cars, Otoqi enhances operational efficiency. Additionally, it enables quick transfers of vehicles between various sites, agencies, and partners, while also offering comprehensive vehicle testing and after-sales services. This holistic approach allows mobility operators to access a full range of services tailored to their needs.
Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.
SportEasy is a user-friendly web and mobile application designed to assist amateur sports teams in managing their activities. Launched in France in 2011, the platform enables coaches to organize games and practices, communicate effectively with players, and analyze team statistics. It also includes social features that allow players to engage with teammates through activities like voting for the player of the game and sharing photos. Available in both French and English, SportEasy aims to streamline the administrative tasks associated with sports management, allowing coaches, managers, and volunteers to focus more on the field and less on paperwork. While the basic features of the application are free, premium plans for teams and clubs have been introduced to provide additional functionality.
CytoKi Pharma ApS is a discovery-stage biotechnology company based in Værløse, Denmark, founded in 2019. The company focuses on developing innovative treatments for diseases with significant unmet medical needs, particularly those resulting from epithelial injury. CytoKi Pharma is currently in the pre-clinical stage and is advancing its lead program, which involves an engineered long-acting IL-22 protein licensed from a major pharmaceutical entity. IL-22 is a crucial cytokine that plays a vital role in the immune system's response to tissue injury, acting as a signal for survival and recovery. By harnessing the therapeutic potential of this modified IL-22 protein, CytoKi Pharma aims to address the challenges posed by organ injuries and improve patient outcomes in affected populations.
Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.
PEP-Therapy is a biotechnology company focused on developing innovative peptide-based therapies aimed at treating severe diseases, particularly cancer. The company specializes in creating Cell Penetrating and Interfering Peptides (CP&IP), which are designed to penetrate cellular membranes and effectively block critical intracellular protein-protein interactions. By doing so, these peptides aim to inhibit essential pathological mechanisms, thereby offering targeted therapeutic options for healthcare providers. Through its research and development efforts, PEP-Therapy seeks to advance the field of targeted therapies and improve outcomes for patients facing serious health challenges.
Foodsmart is a digital nutrition platform dedicated to enhancing health outcomes through personalized dietary recommendations. The company addresses the challenges faced by individuals dealing with chronic diseases and food insecurity by collaborating with health plans and providers. Its telehealth application offers real-time support across various environments such as homes, workplaces, grocery stores, and restaurants. This enables users to make informed food choices, select healthier recipes, and choose menu options that contribute to better health and the management of chronic conditions.
Hepster is an InsurTech company that specializes in creating customized insurance products and seamlessly integrating them into digital processes. Operating under a B2B model, Hepster enhances its offerings with a B2C webshop that allows consumers direct access to its services. The company utilizes a fully API-driven, cloud-based, and modular approach to develop and deploy digital insurance solutions tailored to the specific needs of its partners. Hepster's product portfolio focuses on various sectors, including bike, e-bike, electronics, and sports equipment insurance, thereby providing a comprehensive experience for clients across the insurance value chain.
MedinCell is an injectable slow-release drug specialist company.
ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.
Opencell, founded in 2015, offers an open source monetization and billing platform designed to address the complexities of billing in various sectors, including telecommunications, cloud services, IoT, and utilities. The platform emerged from a telco billing project initiated in 2007 by CEO David Meyer. It aims to bridge the gap between expensive legacy billing systems and simplistic SaaS solutions that often fail to meet diverse customer needs. With over 40 successful implementations across multiple industries and countries, Opencell provides an integrated revenue management platform that enables businesses to effectively administer subscriptions and usage-based revenues, simplifying complex billing processes for a wide range of clients.
We believe in wealth management democratization. We believe that everyone should be able to control their financial life and reach their financial goals. We do that by combining simple-to-use technology with professional personal advice for all financial assets. Our Software-as-a-Service Platform automatically analyzes and plans all types of assets and enables professional advisors to deliver a data-driven and truly personal wealth management.
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.
Dermala Inc. is a consumer dermatology company based in San Diego, California, focused on developing treatments for chronic skin conditions through the human microbiome. The company offers personalized, clinically validated solutions for issues such as acne and eczema. Its flagship product, the FOBO Kit, includes prebiotics and microbiome metabolites designed to eliminate acne-causing bacteria while fostering beneficial skin flora. Additionally, Dermala provides pre-medicated pads that target harmful bacteria and support healthy skin. The products aim to reduce oiliness, unclog pores, and minimize inflammation, thereby preventing new breakouts. Enhancing its offerings, Dermala has developed an application that utilizes data analytics and machine learning to help users track their skin health and optimize treatments. The company was established in 2014 and markets its products directly through its website.
Animab is a biotechnology company focused on enhancing livestock health through innovative monoclonal antibody technology. By leveraging advanced research in animal science, Animab develops products that aim to improve animal welfare, reduce operational costs, and promote sustainability in livestock farming. Their proprietary antibodies are designed to mimic secretory IgA, a natural antibody found in colostrum and milk, which provides critical protection for piglets during the vulnerable post-weaning phase. These antibodies target specific intestinal pathogens while preserving the healthy microbiome, ensuring that piglets remain healthy and resilient during this crucial developmental period. Through its solutions, Animab seeks to benefit animals, producers, and consumers alike.
Federation Bio Inc. is focused on developing microbial therapeutics aimed at curing various diseases through the human microbiome. The company utilizes platforms that harness naturally occurring or engineered bacteria, along with a supportive community of bacteria, to promote engraftment and achieve lasting therapeutic responses. Its research encompasses a broad spectrum of conditions, including secondary hyperoxaluria, metabolic disorders, immune diseases, cholestatic diseases, and cancer. Founded in 2018 and headquartered in South San Francisco, California, Federation Bio was previously known as Comet Medicine Inc. before rebranding in April 2019.
LARQ, Inc. is a company based in Foster City, California, founded in 2017. It specializes in the manufacture and sale of self-cleaning water bottles and purification systems. LARQ's innovative bottles utilize ultraviolet-C LED technology to eliminate bio-contaminants, including germs, bacteria, and protozoa, ensuring safe drinking water for users wherever they are. The company emphasizes both sustainability and design in its products, which are sold primarily through online channels.
Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.
Clim8 is a company focused on developing intelligent wearable technology that provides personalized thermo-regulation in smart clothing. Since its inception in 2015, the co-founders recognized a significant demand for an innovative solution that merges the textile and digital industries. Clim8's technology utilizes a combination of tiny sensors and a detachable battery integrated into a thermal layer to monitor and analyze the wearer's body temperature. By processing this data, the system can activate and regulate heat according to individual preferences, allowing users to manage their comfort levels in various climatic conditions. This advancement moves beyond traditional wearables that only track activities, offering a more responsive and adaptive approach to personal comfort.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Citryll is a private pharmaceutical company based in Oss, The Netherlands, founded in 2015. The company focuses on developing drugs aimed at treating autoimmune diseases and other human health conditions. Citryll's innovative approach involves the manipulation of the formation, function, and clearance of neutrophil extracellular traps (NETs) that are influenced by the protein citrullination pathway, specifically through the action of Peptidylarginine Deiminase (PAD) enzymes. This research supports medical professionals in addressing various serious conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
TransferGo is a global money transfer company that provides a cost-effective solution for migrant workers to send money to their families abroad. By employing a digital account-to-account business model, it allows users to transfer funds internationally without incurring unnecessary bank fees. The company operates as a licensed payment institution, ensuring secure transactions under the supervision of relevant financial authorities. TransferGo’s platform enables users to make transfers at significantly lower costs compared to traditional banks and cash bureaus, often with same-day delivery. The service charges a fixed fee for transfers and a currency conversion fee ranging from 0.6% to 1.5%, making it an attractive option for both individuals and businesses looking to pay suppliers internationally.
Saagie specializes in big data analytics through its DataOps Orchestration platform, which streamlines and accelerates analytic project delivery from raw data to production within weeks. The company aims to unify people, processes, and technology, providing organizations with a reliable framework that emphasizes time-to-value. Saagie's platform is designed to be "open by design," featuring isolated containers and robust network engineering, ensuring transparency in security and governance. This approach fosters trust and auditability in analytic projects. By integrating both open-source and commercial technologies, Saagie supports a wide range of big data and artificial intelligence use cases, allowing global companies to harness the full potential of their data-intensive initiatives. Ultimately, Saagie's solution serves as a Plug and Play Orchestrator for DataOps, facilitating the efficient distribution of AI and big data to enhance competitive advantage across various industries.
MycoTechnology is a food technology company based in Aurora, Colorado, that focuses on enhancing the flavor and nutritional value of agricultural products through fungi-based food-processing platforms. Founded in 2013, the company addresses various challenges in the food, beverage, and flavor industries by utilizing gourmet fungi and mycelial fermentation. One of its notable products, ClearTaste, is an all-natural, GMO-free, organic bitter blocker that is both Kosher and Halal certified, designed to improve the taste of various agricultural products. In addition, MycoTechnology offers myceliated chocolate and works with robusta and arabica coffee beans, developing and licensing technology to enhance their flavor profiles. By integrating these innovative solutions, the company aims to help food producers incorporate healthier ingredients and strengthen their brand associations.
ViroVet is an innovative company focused on developing groundbreaking technologies to combat viral diseases in livestock, particularly through antiviral drugs targeting respiratory disease complexes and novel vaccines for swine. The livestock industry, valued at over 100 billion euros, faces significant financial losses due to viral diseases, which threaten global animal protein supplies. ViroVet aims to supply livestock producers, national governments, and international organizations with comprehensive solutions that can be used independently or alongside existing vaccines and biosecurity measures. With the growing world population and increased demand for protein, the risk of viral disease spread in densely populated livestock environments is rising. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to reduce antibiotic use and transform the industry. Through its innovative approach, ViroVet addresses urgent challenges posed by endemic and epizootic viral diseases, ultimately aiming to enhance the resilience of the livestock sector.
One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.
MOVE 'N SEE provides digital tools and an auto-follow camera for individual sports, team sports, and arena use. It provides attentive customer service, technological excellence, and an insatiable passion for sports, theater, and video.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
NovoBind is an agri-biotech company focused on addressing the challenges of rising resistance to anti-infectives and the accumulation of harmful residues in the environment. The company develops next-generation biologics designed to target and neutralize specific pathogens, including bacteria, viruses, and parasites that lead to significant production losses in livestock, aquaculture, and pets. By providing innovative solutions, NovoBind aims to help animal sector businesses minimize waste and improve food safety, ultimately addressing issues that result in over $1 billion in production losses annually.
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.
TIBOT Technologies SAS, established in 2016 and based in Cesson-Sévigné, France, specializes in designing and developing robotic solutions for poultry farming. The company focuses on enhancing the daily operations of poultry farmers through innovative technology. Its flagship products include Spoutnic, an assistant robot, and Spoutnic NAV, which autonomously scrapes, drinks, and feeds poultry. These robots are designed to improve animal welfare, increase hatching rates, and optimize working conditions for farmers, ultimately enhancing profitability in poultry operations. TIBOT Technologies aims to facilitate the poultry farming process by integrating automation and efficiency into traditional farming practices.
FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.
String Bio Private Limited, founded in 2013 and based in Bengaluru, India, specializes in manufacturing chemical monomers for biodegradable polymers and various industrial applications. The company produces lactic acid, which is used in medical implants, decomposable packaging materials, textiles, food, and personal care products, as well as succinic acid, utilized in specialty chemicals, pharmaceuticals, and lubricants. Additionally, String Bio develops single cell protein for animal feed. By leveraging methane as a carbon source, the company aims to create sustainable industrial products that enhance global food security and meet the rising demand for protein.
DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.